

METHODOLOGY

1 application/day for **3 months**
In **monotherapy**
In **association** or as a **relay** to treatment and/or **emerging therapies**

13
countries

- **Europe** : Greece, Spain, Italy, Germany, French overseas
- **Middle East** : Saudi Arabia, United Arab Emirates
- **Africa** : Morocco, Tunisia, Senegal, Ivory Coast
- **East Asia** : South Korea
- **South America** : Venezuela

180 DERMATOLOGISTS

1676 adult patients with **CHRONIC HAIR LOSS**
All ethnicities (hair & phototype)



PRESCRIPTION SCHEME

61%
in monotherapy (n=1025)

26%
in association (n=434)

13%
as a relay (n=217)


MAIN ASSOCIATED TREATMENTS:

Minoxidil ⁽¹⁾ **70%** / Finasteride ⁽²⁾ **15%**

EMERGING THERAPIES:

Platelet-Rich Plasma and mesotherapy **55%**

Others* **45%**



POPULATION



18-93 years
mean: 40
66% ♀ | **34%** ♂



All phototypes

CHRONIC HAIR LOSS

64%
Androgenetic alopecia



31%
Chronic telogen effluvium



2.6%
Senescent alopecia ⁽³⁾



1.7%
Post-cancer treatment alopecia



• International, post-marketing study on ANAPHASE NEOPTIDE serum, applied once daily on 1676 subjects with chronic hair loss
• n=number of subjects

(1) Oral and topical
(2) Pooled finasteride & dutasteride
(3) Senescent alopecia affects people aged 50 years or older with no family history or evidence of pattern balding.

* Stem-cell therapy, low level light therapy, micro needling and other emerging therapies.

DERMATOLOGISTS CLINICAL EVALUATION

<p>Androgenetic alopecia in monotherapy (n=575)</p>  <p>+33% HAIR DENSITY*</p>	<p>Senescent alopecia⁽²⁾ (n=42)</p>  <p>+38% HAIR VOLUME*</p>
<p>Chronic telogen effluvium in monotherapy (n=345)</p>  <p>-64% HAIR LOSS*⁽¹⁾</p>	<p>Post-cancer treatment alopecia⁽²⁾ (n=28)</p>  <p>+47% HAIR VOLUME*</p>

**DERMATOLOGISTS
OVERALL SATISFACTION
AT 3 MONTHS**⁽³⁾

95%
JUDGED THE PRODUCT EFFECTIVE

95%
GOOD TO VERY GOOD TOLERANCE

97%
WILL CONTINUE TO PRESCRIBE
ANAPHASE NEOPTIDE SERUM



SUBJECTS SELF ASSESSMENT



-49% HAIR LOSS
regardless of the type of
CHRONIC HAIR LOSS

**ANAPHASE NEOPTIDE
serum is an effective
and well-tolerated
option in monotherapy
regardless of the type of
CHRONIC HAIR LOSS**

• Hair loss, density and volume were assessed using an NRS scale from 0 (very slight) to 10 (very high).
The reported number indicates the percentage change from baseline.
• International, post-marketing study on ANAPHASE NEOPTIDE serum, applied once daily on 1676 subjects with chronic hair loss.
• n=number of subjects // * = p<0,001 vs baseline

(1) Hair pull test
(2) Results regardless of the prescription scheme for ANAPHASE NEOPTIDE serum
(3) n=1024